Exclusive Summary

• With approximately 850 million CKD patients globally, there is a massive, long-term market demand for Compound α-Ketoacid Tablets among non-dialysis advanced CKD patients.
• Although the original core patent has expired, the high technical barrier in formulating multiple active ingredients results in few global generic competitors, leaving a lucrative market dominated by the expensive originator.
• The KDIGO guidelines strongly recommend the combination of a low-protein diet and ketoacid analogs to delay dialysis progression, solidifying its standard-of-care clinical status.
• Flexible packaging options (48-100 tablets/carton) combined with significant cost advantages drastically reduce patients' daily financial burden, acting as an ideal generic alternative for emerging markets and cost-sensitive healthcare systems.